Ferring Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ferring Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#271 of 15,742 sponsors by registered trial count).
Ferring Pharmaceuticals: 83 sponsored US clinical trials, 4 recruiting.
Ferring Pharmaceuticals sponsors 83 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 68 completed. 45 of these trials are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cervical Ripening, with 4 trials.
Top-decile sponsor footprint
Ferring Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#271 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
68 of 79 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
83 total, page 1 of 2
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT06668493
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955
Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy
NCT04113382
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
NCT06026332
REBYOTA™ Prospective Registry
NCT05835219
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
NCT05924321
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
NCT05831189
A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)
NCT05403476
Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
NCT02545127
Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
NCT04163458
A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US
NCT04125186
Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
NCT03692403
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)
NCT03738618
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
NCT03740737
Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures
NCT03565211
AMPLEX Ankle Fusion and Hindfoot
NCT03028415
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
NCT03201419
A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy
NCT03017235
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT02773849
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
NCT02663908
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
NCT02522780
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
NCT02522767
MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
NCT02554279
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
NCT02508649
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males
NCT02149264
Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy
NCT01928862
LutrePulse Hypogonadotropic Hypogonadism
NCT01976728
Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
NCT01968187
Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
NCT01895543
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
NCT01827592
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
NCT01833065
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
NCT01729819
A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel
NCT01703741
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel
NCT01665599
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
NCT01552343
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
NCT01491971
A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator
NCT01464879
Menopur Mixed Protocol
NCT01417195
Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)
NCT01283022
Efficacy, Pharmacokinetics and Safety of Testosterone
NCT01370369
Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
NCT01262456
Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
NCT01223937
A Degarelix Trial in Patients With Prostate Cancer
NCT01242748
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
NCT01127581
Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding
NCT01190150
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep
NCT01073930
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep
NCT01073943
Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy
NCT00925938
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
NCT01000649
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 28 |
| Phase 3 | 40 |
| Phase 4 | 5 |
What is open in the Ferring Pharmaceuticals pipeline
4 recruiting of 83 indexed (5% open); 68 completed (82%).
Phase mix: 45 late (III/IV) vs 33 early (I/II) (balanced across stages).
Top condition: Cervical Ripening (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ferring Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 83 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Ferring Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 83 trials (± recruiting share)
- National Jewish Health · 83 trials · 8% recruiting
- New York University · 83 trials · 30% recruiting
- Teva Pharmaceuticals USA · 83 trials · 0% recruiting
- Seagen · 84 trials · 0% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Amphastar Pharmaceuticals · 5% recruiting · 21 trials
- Cook County Health · 5% recruiting · 21 trials
- David Grant U.S. Air Force Medical Center · 5% recruiting · 21 trials
- Duquesne University · 5% recruiting · 21 trials
Related
What to do with this Ferring Pharmaceuticals page
83 registered trials is a research-attention snapshot, not an endorsement of Ferring Pharmaceuticals or any single study.
- 4 of Ferring Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cervical Ripening is the condition Ferring Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cervical Ripening trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ferring Pharmaceuticals pipeline card: 83 registered trials from official public datasets.Report a data error.